Q1 2026 Management view Dr. Alison Moore said the company “accomplished a lot” since the prior call and plans to present “important new data on our ECO Synthesis technology” at the TIDES Conference, ...

A week ago, Codexis, Inc. (NASDAQ:CDXS) came out with a strong set of first-quarter numbers that could potentially lead to a re-rate of the stock. Revenues and losses per share we ...

Codexis CDXS will release its quarterly earnings report on Wednesday, 2025-08-13. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Codexis to report an earnings per ...

Reports revenue of $15.2 million for the first quarter, company reiterates full-year financial guidanceThree presentations at upcoming TIDES USA ...

Codexis outlined ongoing commercial discussions supported by a "very, very healthy" sales funnel spanning large pharma, ...

Codexis (CDXS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

There's been a notable change in appetite for Codexis, Inc. (NASDAQ:CDXS) shares in the week since its full-year report, with the stock down 14% to US$22.11. Revenues of US$69m were in line with ...

REDWOOD CITY, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (CDXS), a leading enzyme engineering company, today announced it has entered into an asset purchase agreement with Crosswalk ...

REDWOOD CITY, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, ...

REDWOOD CITY, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, ...

REDWOOD CITY, Calif. and BEVERLY, Mass.--(BUSINESS WIRE)--Codexis, Inc. (Nasdaq: CDXS) and seqWell, Inc. today announced the initiation of a strategic partnership and investment to accelerate the ...